Regorafenib
Overview
Regorafenib is a multi-kinase inhibitor that targets various pathological kinases to impede cancer cell proliferation and angiogenesis. It is primarily used for the treatment of metastatic colorectal cancer and gastrointestinal stromal tumors.
API suppliers (6)
Suppliers of Regorafenib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
3 of 6 hold a GMP certificate on record in the EU or UK registers
- MSN Laboratories Private LimitedIndia2 active DMF GMP on record
- Hetero Labs LimitedIndia1 active DMF GMP on record
- CHONGQING CARELIFE PHARMACEUTICAL CO LTDChina1 active DMF
- Zhejiang Huayi Pharmaceutical Co., Ltd.China1 active DMF
- Shandong Anhong Pharmaceutical Co., Ltd.China1 active DMF GMP on record
- Sichuan Kelun Pharmaceutical Co., Ltd.China1 active DMF
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Regorafenib expires 9 Jul 2032. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Regorafenib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.